Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment

  • 215 Accesses

  • 5 Citations


We investigated the effects of hepatic and renal impairment on the pharmacokinetics of enrofloxacin in Sprague-Dawley rats. Experimental hepatic and renal failure were induced by carbon tetrachloride (CCL4) and 5/6 nephrectomy, respectively. After intravenous dosing of enrofloxacin (10 mg/kg), plasma concentrations of enrofloxacin were measured using liquid chromatograph/mass spectrometry. There was no significant effect of hepatic impairment on enrofloxacin pharmacokinetics. However, renal impairment markedly prolonged elimination half life (t1/2λz) of enrofloxacin (P < 0.05), comparing with respective control. Total body clearance (Clb) and volume of distribution at steady state (Vss) were significantly decreased (P < 0.05) by renal impairment. In conclusion, these results suggested that renal impairment could affect the pharmacokinetics of enrofloxacin.

This is a preview of subscription content, log in to check access.

Fig. 1


  1. Bauditz, R., 1989. Results of clinical studies with Baytril in dogs and cats. Vet. Res. Commun., 2, 137–140.

  2. Beluche, L.A., Bertone, A.L., Anderson, D.E., Kohn, C.W., Weisbrode, S.E., 1999. In vitro dose-dependent effects of enrofloxacin on equine articular cartilage. Am. J. Vet. Res., 60, 577–582.

  3. Bertone, A.L., Tremaine, W.H., Macoris, D.G., Simmons, E.J., Ewert, K.M., Herr, L.G., Weisbrode, S.E., 2000. Effect of long-term administration of an injectable enrofloxacin solution on physical and musculoskeletal variables in adult horses. J. Am. Vet. Med. Assoc., 217, 1514–1521. doi:10.2460/javma.2000.217.1514.

  4. Blum, R.A., 1992. Influence of renal function on the pharmacokinetics of lomefloxacin compared with other fluoroquinolones. Am. J. Med., 92, 18–21. doi:10.1016/0002-9343(92)90302-R.

  5. Boothe, S.A., 1994. Enrofloxain revistied. Vet. Med., 89, 744–753.

  6. Bregante, M.A., Saez, P., Aramayona, J.J., Fraile, L., Garcia, M.A., Solans, C., 1999. Comparative pharmacokinetics of enrofloxacin in mice, rats, rabbits, sheep, and cows. Am. J. Vet. Res., 60, 1111–1116.

  7. Brown, S.A., 1996. Fluoroquinolones in animal health. J. Vet. Pharmacol. Ther., 19, 1–14. doi:10.1111/j.1365-2885.1996.tb00001.x.

  8. Cox, S.K., Cottrell, M.B., Smith, L., Papich, M.G., Frazier, D.L., Bartges, J., 2004. Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species. J. Vet. Pharmacol. Ther., 27, 139–146. doi:10.1111/j.1365-2885.2004.00560.x.

  9. Elmas, M., Tras, B., Kaya, S., Bas, A.L., Yazar, E., Yarsan, E., 2001. Pharmacokinetics of enrofloxacin after intravenous and intramuscular administration in Angora goats. Can. J. Vet. Res., 65, 64–67.

  10. Elmas, M., Yazar, E., Bas, A.L., Tras, B., Bayezit, M., Yapar, K., 2002. Comparative pharmacokinetics of enrofloxacin and tissue concentrations of parent drug and ciprofloxacin after intramuscular administrations of free and liposome-encapsulated enrofloxacin in rabbits. J. Vet. Med. B Infect. Dis. Vet. Public Health, 49, 507–512. doi:10.1046/j.1439-0450.2002.00603.x.

  11. Fillastre, J.P., Leroy, A., Moulin, B., Dhib, M., Borsa-Lebas, F., Humbert, G., 1990. Pharmacokinetics of quinolones in renal insufficiency. J. Antimicrob. Chemother., 26, 51–60.

  12. Gelatt, K.N., van der Woerdt, A., Ketring, K.L., Andrew, S.E., Brooks, D.E., Biros, D.J., Denis, H.M., Cutler, T.J., 2001. Enrofloxacin-associated retinal degeneration in cats. Vet. Ophthalmol., 4, 99–106. doi:10.1046/j.1463-5224.2001.00182.x.

  13. Jiko, M., Yano, I., Okuda, M., Inui, K., 2005. Altered pharmacokinetics of paclitaxel in experimental hepatic or renal failure. Pharm Res., 22, 228–234. doi:10.1007/s11095-004-1190-6.

  14. Jones, E.M., McMullin, C.M., Hedges, A.J., Lovering, A.M., White, L.O., Reeves, D.S., MacGowan, A.P., 1997. The pharmacokinetics of intravenous ciprofloxacin 400 mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J. Antimicrob. Chemother., 40, 121–124. doi:10.1093/jac/40.1.121.

  15. Kim, M.S., Lim, J.H., Park, B.K., Hwang, Y.H., Yun, H.I., 2006. Pharmacokinetics of enrofloxacin in Korean catfish (Silurus asotus). J. Vet. Pharmacol. Ther., 29, 397–402. doi:10.1111/j.1365-2885.2006.00783.x.

  16. McKellar, Q., 1996. Clinical relevance of the pharmacologic properties of fluoroquinolones. Educ. Pract. Vet., 18, 14–20.

  17. Mehrotra, R., De Gaudio, R., Palazzo, M., 2004. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care. Med., 30, 2145–2156. doi:10.1007/s00134-004-2428-9.

  18. Monlouis, J.D., DeJong, A., Limet, A., Richez, P., 1997. Plasma pharmacokinetics and urine concentraions of enrofloxacin after intravenous and intramuscular administration of enrofloxacin in dogs. J. Vet. Pharmacol. Ther., 20, 61–63. doi:10.1046/j.1365-2885.1997.00041.x.

  19. Nakamura, N., Masuda, S., Takahashi, K., Saito, H., Okuda, M., Inui, K., 2004. Decreased expression of glucose and peptide transporters in rat remnant kidney. Drug Metab. Pharmacokinet., 19, 41–47. doi:10.2133/dmpk.19.41.

  20. Naora, K., Ichikawa, N., Hirano, H., Iwamoto, K., 1999. Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure. J. Pharm. Pharmacol., 51, 609–616. doi:10.1211/0022357991772718.

  21. Nouaille-Degorce, B., Veau, C., Dautrey, S., Tod, M., Laouari, D., Carbon, C., Farinotti, R., 1998. Influence of renal failure on ciprofloxacin pharmacokinetics in rats. Antimicrob. Agents Chemother., 42, 289–292.

  22. Papich, M.G., Van Camp, S.D., Cole, J.A., Whitacre, M.D., 2002. Pharmacokinetics and endometrial tissue concentrations of enrofloxacin and the metabolite ciprofloxacin after i.v. administration of enrofloxacin to mares. J. Vet. Pharmacol. Ther., 25, 343–350. doi:10.1046/j.1365-2885.2002.00434.x.

  23. Richez, P., Dellac, B., Froyman, R., DeJong, A., 1994. Pharmacokinetics of enrofloxacin in calves and adult cattle after single and repeated subcutaneous injections. Proceedings of European Association for Veterinary Pharmacology and Toxicolgy, Proceedings of 6th Interational congress, Deinburgh, UK 1994, 232–233.

  24. Richez, P., Monlouis, J.D., Dellac, B., Daube, G., 1997. Validation of a therapeutic regimen for enrofloxacin in cats on the basis of pharmacokinetic data. J. Vet. Pharmacol. Ther., 20, 152–153.

  25. Tanaka, H., Tokiwa, T., 1990. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res., 50, 6615–6619.

  26. Tyczkowska, K., Hedeen, K.M., Aucoin, D.P., Aronson, A.L., 1989. High-performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue. J. Chromatogr., 493, 337–346.

  27. Vancutsem, P.M., Schwark, W.S., 1992. Effects of fluoroquinolone antimicrobials alone and in conjunction with theophylline on seizures in amygdaloid kindled rats. Mechanistic and pharmacokinetic study. Epilepsy Res., 13, 59–71. doi:10.1016/0920-1211(92)90008-H.

  28. Vancutsem, P.M., Babish, J.G., Schwark, W.S., 1990. The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell. Vet., 80, 173–186.

  29. Wiebe, V., Hamilton, P., 2002. Fluoroquinolone-induced retinal degeneration in cats. J. Am. Vet. Med. Assoc., 221, 1568–1571. doi:10.2460/javma.2002.221.1568.

Download references

Author information

Correspondence to H. I. Yun.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hwang, Y.H., Kim, M.S., Song, I.B. et al. Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment. Vet Res Commun 33, 481–487 (2009). https://doi.org/10.1007/s11259-008-9195-y

Download citation


  • Enrofloxacin
  • Pharmacokinetics
  • Renal impairment
  • Hepatic impairment
  • Rats